Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening

L Lindfors; P Skantze; U Skantze; M Rasmusson; A Zackrisson; Ulf Olsson

doi:10.1021/la0523661

Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening

L Lindfors, P Skantze, U Skantze, M Rasmusson, A Zackrisson, Ulf Olsson

Physical Chemistry

Research output: Contribution to journal › Article › peer-review

Abstract

Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.

Original language	English
Pages (from-to)	906-910
Journal	Langmuir
Volume	22
Issue number	3
DOIs	https://doi.org/10.1021/la0523661
Publication status	Published - 2006

Subject classification (UKÄ)

Physical Chemistry (including Surface- and Colloid Chemistry)

Access to Document

10.1021/la0523661

Cite this

@article{36d5b0eafa1f4d97a08e8ae6aa000e85,

title = "Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening",

abstract = "Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.",

author = "L Lindfors and P Skantze and U Skantze and M Rasmusson and A Zackrisson and Ulf Olsson",

year = "2006",

doi = "10.1021/la0523661",

language = "English",

volume = "22",

pages = "906--910",

journal = "Langmuir",

issn = "0743-7463",

publisher = "The American Chemical Society (ACS)",

number = "3",

}

TY - JOUR

T1 - Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening

AU - Lindfors, L

AU - Skantze, P

AU - Skantze, U

AU - Rasmusson, M

AU - Zackrisson, A

AU - Olsson, Ulf

PY - 2006

Y1 - 2006

N2 - Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.

AB - Amorphous drug nanosuspensions are prone to particle growth due to Ostwald ripening. By incorporating a second component of extremely low aqueous solubility, Ostwald ripening can be inhibited. These studies indicate that to inhibit ripening, the drug/inhibitor mixture (in the particles) must form a single phase. The drug/inhibitor mixture can be characterized by the interaction parameter chi using the Bragg-Williams theory, in which single phase mixtures are obtained for chi < 2. The chi parameter can be calculated from the (crystalline) solubility of the drug in the inhibitor, provided the inhibitor is a liquid, and the melting entropy and temperature of the drug.

U2 - 10.1021/la0523661

DO - 10.1021/la0523661

M3 - Article

C2 - 16430247

SN - 0743-7463

VL - 22

SP - 906

EP - 910

JO - Langmuir

JF - Langmuir

IS - 3

ER -